These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28005451)

  • 21. Improving the targeting of therapeutics with single-domain antibodies.
    Turner KB; Alves NJ; Medintz IL; Walper SA
    Expert Opin Drug Deliv; 2016; 13(4):561-70. PubMed ID: 26689649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid nanocarriers for the loading of polyphenols - A comprehensive review.
    Pimentel-Moral S; Teixeira MC; Fernandes AR; Arráez-Román D; Martínez-Férez A; Segura-Carretero A; Souto EB
    Adv Colloid Interface Sci; 2018 Oct; 260():85-94. PubMed ID: 30177215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics.
    Muthiah M; Park IK; Cho CS
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1259-73. PubMed ID: 23826971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zein-derived peptides as nanocarriers to increase the water solubility and stability of lutein.
    Jiao Y; Zheng X; Chang Y; Li D; Sun X; Liu X
    Food Funct; 2018 Jan; 9(1):117-123. PubMed ID: 29336438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Delivery for Intracellular Targets: Emergent Therapeutic Potential.
    Singh K; Ejaz W; Dutta K; Thayumanavan S
    Bioconjug Chem; 2019 Apr; 30(4):1028-1041. PubMed ID: 30830750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular delivery of proteins by nanocarriers.
    Ray M; Lee YW; Scaletti F; Yu R; Rotello VM
    Nanomedicine (Lond); 2017 Apr; 12(8):941-952. PubMed ID: 28338410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.
    Cooper DL; Conder CM; Harirforoosh S
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1661-80. PubMed ID: 25054316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular co-delivery of Sr ion and phenamil drug through mesoporous bioglass nanocarriers synergizes BMP signaling and tissue mineralization.
    Lee JH; Mandakhbayar N; El-Fiqi A; Kim HW
    Acta Biomater; 2017 Sep; 60():93-108. PubMed ID: 28713017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled release of therapeutic antibody formats.
    Schweizer D; Serno T; Goepferich A
    Eur J Pharm Biopharm; 2014 Oct; 88(2):291-309. PubMed ID: 25125350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.
    Din FU; Aman W; Ullah I; Qureshi OS; Mustapha O; Shafique S; Zeb A
    Int J Nanomedicine; 2017; 12():7291-7309. PubMed ID: 29042776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graft copolymer nanoparticles with pH and reduction dual-induced disassemblable property for enhanced intracellular curcumin release.
    Zhao J; Liu J; Xu S; Zhou J; Han S; Deng L; Zhang J; Liu J; Meng A; Dong A
    ACS Appl Mater Interfaces; 2013 Dec; 5(24):13216-26. PubMed ID: 24313273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies.
    Pietersz GA; Wang X; Yap ML; Lim B; Peter K
    Nanomedicine (Lond); 2017 Aug; 12(15):1873-1889. PubMed ID: 28703636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances of siRNA delivery by nanoparticles.
    Yuan X; Naguib S; Wu Z
    Expert Opin Drug Deliv; 2011 Apr; 8(4):521-36. PubMed ID: 21413903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
    Gu J; Al-Bayati K; Ho EA
    Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications.
    Sala M; Diab R; Elaissari A; Fessi H
    Int J Pharm; 2018 Jan; 535(1-2):1-17. PubMed ID: 29111097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium carbonate nanoparticles as cancer drug delivery system.
    Maleki Dizaj S; Barzegar-Jalali M; Zarrintan MH; Adibkia K; Lotfipour F
    Expert Opin Drug Deliv; 2015; 12(10):1649-60. PubMed ID: 26005036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular delivery of nanocarriers and targeting to subcellular organelles.
    Jhaveri A; Torchilin V
    Expert Opin Drug Deliv; 2016; 13(1):49-70. PubMed ID: 26358656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents.
    Maranhão RC; Vital CG; Tavoni TM; Graziani SR
    Expert Opin Drug Deliv; 2017 Oct; 14(10):1217-1226. PubMed ID: 28042707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges.
    Laurent S; Saei AA; Behzadi S; Panahifar A; Mahmoudi M
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1449-70. PubMed ID: 24870351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.